Operators are excited about a device that avoids transapical access, a limitation of other systems, says Gilbert Tang.

The everolimus scaffold, which had mostly disappeared by 3 years, was still associated with fewer reinterventions than PTA.

The data are largely in line with those seen at 5 years, but the follow-up reassures there’s no concern about valve ...

The device, which is delivered transapically, represents an option for very sick patients who previously have had none.

Reaching participants through retail pharmacies, the study speaks to how much VHD goes underrecognized—with a few surprises.

The DCB is meant to address long-term stent-related complications and avoid adding yet another metal layer in ISR.